Hospital Formulary Status Yes (PO solid, PO susp, parenteral inj)
In-Hospital Cost will be updated
PharmaCare Formulary Status Yes (PO solid, PO susp, parenteral inj)
Special Authority None
PharmaCare Coverage 20/100mg PO - $0.1018/tab 80/400mg PO - $0.0521/tab 160/800mg PO DS - $0.2240/tab 16/80mg/ml IV ampul - $1.7690/ml 40/200mg/5ml PO susp - $0.2160/ml
Outpatient Cost 20/100mg PO - $0.11-0.96/tab 80/400mg PO - $0.05-0.58/tab 160/800mg PO DS - $0.13-3.60/tab 16/80mg/ml IV ampul - $1.77-1.95/ml 40/200mg/5ml PO susp - $0.22-0.24/ml
Follow creatinine and electrolytes in patients at increased risk renal failure, hyperkalemia.
Generally, well tolerated in patients without HIV (ADR rate: 6-8%) In patients with HIV, ADRs are common and severe (ADR rate: 25-50%)
Gastritis (PO and IV)
Skin toxicity (PO and IV)
Nephrotoxicity (mainly with IV)
Hyperkalemia (mainly with IV)
Severe lactic acidosis (IV)
Folate deficiency (mainly with IV)
Other
ACEi - Increased serum potassium level.
Increases amantadine levels.
Decreases cyclosporine.
Methotrexate- marrow suppression.
Increases phenytoin.
Increases rifampin.
Increases INR with warfarin.
Antimicrobial class: Sulfonamide, Antifolate
Pregnancy category: C
Average serum half life: 10.0 hr
Urine penetration: Therapeutic
Lung penetration: Therapeutic
CSF penetration: Therapeutic
Biliary penetration: Moderate